19
Jul 22
Agilent’s Certified Pre-Owned Instruments Program Receives Environmental Award
Agilent’s Certified Pre-Owned Instruments Program Receives Environmental Award Agilent Technologies Inc. (NYSE: A) today announced the company’s Certified Pre-Owned Instruments...
Read More
5
Apr 22
Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell Carcinoma
Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell Carcinoma Agilent Technologies Inc....
Read More
5
Apr 22
Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Muscle-Invasive Urothelial Carcinoma (MIUC)
Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Muscle-Invasive Urothelial Carcinoma (MIUC) Agilent Technologies Inc....
Read More
7
Jan 22
The Innovators 2021
The Innovators 2021 R-TRACKER: A TRUE MILESTONE IN SPECIMEN TRACEABILITY Traceability is of paramount importance for patient safety...
Read More
2
Nov 21
Agilent Names John Palma to Lead Global Medical Affairs Organization
Agilent Names John Palma to Lead Global Medical Affairs Organization Agilent Technologies, Inc. (NYSE: A) today announced that John Palma...
Read More
21
Oct 21
Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric, Gastroesophageal Junction,...
Read More
13
Oct 21
Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer
Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer Agilent Technologies Inc. (NYSE:...
Read More
29
Sep 21
GE Healthcare Debuts MyoSPECT, A Next-Generation Nuclear Medicine Cardiology System That Gets to the Heart of Challenging Cardiovascular Cases
GE Healthcare Debuts MyoSPECT, A Next-Generation Nuclear Medicine Cardiology System That Gets to the Heart of Challenging Cardiovascular Cases GE...
Read More
17
Sep 21
Start of the Magnetic Resonance Outcome (MRO) study to evaluate the ClearCoast™ MRI system
Start of the Magnetic Resonance Outcome (MRO) study to evaluate the ClearCoast™ MRI system The ClearCoast™ MRI system makes it...
Read More
17
Sep 21
New name: ClearSight™ has become ClearCoast™
New name: ClearSight™ has become ClearCoast™ ClearCut Medical Ltd. has changed the name of its diffusion-weighted MRI technology for intraoperative...
Read More
